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Abstract A non-peptide, vasopressin V1a receptor-selective
antagonist, OPC-21268, exhibited a markedly higher affinity
for the rat V1a receptor (Ki = 380 nM) than for the human V1a
receptor (Ki = 140 WM). To delineate the region responsible for
the high affinity binding of OPC-21268 for the rat V1a receptor,
we have constructed a series of chimeric human and rat V1a
receptors, and examined the chimeric and point-mutated
receptors by competitive radioligand binding analysis. The
results showed that the transmembrane domain (TMD) VI^VII
of the vasopressin V1a receptor, in particular the amino acid
residue Ala-342 in TMD VII, is the major component conferring
the rat-selective binding of OPC-21268 to the V1a receptor.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The neurohypophysal hormone, arginine vasopressin
(AVP), induces diverse actions, including the inhibition of
diuresis, the stimulation of hepatic glycogenolysis, the con-
traction of smooth muscle cells, the modulation of adrenocor-
ticotropic hormone release from the pituitary and the aggre-
gation of platelets [1]. AVP exerts its actions through binding
to G protein-coupled speci¢c membrane receptors linked to
distinct second messengers [2^4]. AVP receptors can be divid-
ed pharmacologically into at least three subtypes: the V1a,
V1b and V2 receptors. The V1a receptors are involved in
vasoconstriction and hepatic glycogenolysis, while the V1b
receptors mediate the stimulation of corticotropin secretion
by the adenohypophysis. The V2 receptors are responsible
for the antidiuretic e¡ect of AVP [5,6]. Among the receptor
subtypes, the V1a receptor is considered to play an important
role in the pathogenesis of human diseases, such as hyper-
tension and congestive heart failure. Although many vaso-
pressin antagonists have been developed as potential thera-
peutic agents for these disorders, they are all peptide analogs
that do not have su⁄cient oral bioavailability.
OPC-21268 (1-{1-[4-(3-acetylaminopropoxy)benzoyl]-4-pi-
peridyl}-3,4-dihydro-2-(1H)-quinolinone) was recently devel-
oped as the ¢rst orally e¡ective, non-peptide V1 vasopressin
receptor antagonist [7,8]. Previously, using cloned rat and
human V1a receptors, we reported that OPC-21268 exhibited
a markedly higher a⁄nity for the rat V1a receptor than for
the human V1a receptor [9]. In the present study, in order to
delineate the responsible region for the species-dependent dif-
ference in the a⁄nity of OPC-21268 for the V1a receptor, we
have constructed a series of several chimeric human and rat
V1a receptors, and examined their a⁄nities by competitive
radioligand binding analysis. The results demonstrate that
the transmembrane domain (TMD) VI^VII portion is critical
for the observed species di¡erence in binding of OPC-21268
for the V1a receptor.
2. Materials and methods
2.1. Materials
The following drugs were used: [Arg8]vasopressin (AVP) (Sigma,
St. Louis, MO, USA); OPC-21268 (Otsuka Pharmaceutical, Tokush-
ima, Japan); [phenylalanyl-3,4,5,-3H(N)]-8-L-AVP ([3H]AVP) (speci¢c
activity, 64.2 Ci/mmol; New England Nuclear, Boston, MA, USA).
All other chemicals were of reagent grade.
2.2. Construction of chimeric human/rat V1a receptors and amino
acid-substituted human V1a receptor mutants
The cDNA constructs encoding chimeric human and rat V1a re-
ceptors were constructed by digestion at common restriction sites
within the wild-type human and rat V1a receptor cDNAs [3,9,10]
and exchanging the corresponding regions of each. The restriction
sites and their positions in the deduced amino acid sequence of the
rat/human V1a receptors, respectively, were as follows: BssHIII, at
Ala-163/Ala-164 in the intracellular loop (ICL) II; XhoI, at Ser-213/
Thr-214 in the extracellular loop (ECL) II; DraIII, at Cys-275/Cys-
280 in ICL III; Aor51HI, at Ala-334/Ala-339 in ECL III; A£II, at
Ala-348/Ala-353 in TMD VII. Although BssHIII, DraIII and A£II
sites are commonly present within the wild-type human and rat V1a
receptors, the XhoI and Aor51HI sites were created by oligonucleo-
tide-directed mutagenesis. The structures of the chimeras are shown in
Fig. 1. The positions of the junctions for individual chimeric human/
rat V1a receptors and their component amino acids are as follows:
chimeric receptor 1 (CR1), rat 1^163/human 164^418; CR2, rat 1^
214/human 213^418; CR3, rat 1^280/human 275^418; CR4, rat 1^
353/human 349^418; CR5, human 1^164/rat 163^394; CR6, human
1^213/rat 215^394; CR7, human 1^275/rat 280^394; CR8, human 1^
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317/rat 323^394; CR9, human 1^348/rat 354^394. Amino acid-substi-
tuted mutants of the human V1a receptor were constructed by PCR
using site-directed mutagenesis. Four amino acids, Thr-298, Val-302,
Ile-310 and Gly-337, in TMD VI^VII of the human V1a receptor
di¡er from those of the rat V1a receptor. These four amino acids
were changed individually to the corresponding amino acids of the
rat V1a receptor, Ser-303, Leu-307, Val-315 and Ala-342, respectively.
Each mutation was con¢rmed by sequencing. Finally, the wild-type
human V1a receptor, the wild-type rat V1a receptor and all of the
mutant receptors were inserted into EcoRI and XhoI sites of a mam-
malian expression vector pME 18S [11], respectively.
2.3. Cell transfection
The wild-type human V1a receptor, the wild-type rat V1a receptor
and mutant receptors were transiently transfected into COS-7 cells by
electroporation (240 V, 975 WF, Bio-Rad gene Pulser II electoropo-
rator, Bio-Rad, Hercules, CA, USA) according to the manufacturer’s
instructions. Cells were harvested 48^72 h after transfection.
2.4. Membrane preparations
The transfected cells were collected and homogenized by a Branson
sonicator (model SONIFIER 250, Branson, Danbury, CT, USA; set-
ting 5 for 8 s) in 2 ml of ice-cold bu¡er A (250 mM sucrose, 10 mM
Fig. 1. Structure of chimeric human/rat V1a receptors (CRs 1^9). Filled bars, sequences of the wild-type rat V1a receptor (Rwt); open bars, se-
quences of the wild-type human V1a receptor (Hwt). The position of junctional amino acids in these CRs and the methods used for their con-
structions are described in Section 2.
Table 1
Binding a⁄nities of AVP and OPC-21268 for the wild-type human, the wild-type rat and the chimeric human/rat V1a receptors
OPC-21268 AVP OPC/AVP
Ki (nM) Ki (nM)
Hwt 14 0000 1.4 þ 0.2 100 000
CR1 190 000 þ 25 000 0.60 þ 0.01 320 000
CR2 150 000 þ 38 000 1.0 þ 0.2 150 000
CR3 29 000 þ 1 900 0.80 þ 0.10 36 000
CR4 240 þ 11 1.7 þ 0.5 140
Rwt 380 þ 7 1.4 þ 0.6 271
Cell membranes from COS-7 cells, transfected with the pME 18S expression vector containing the wild-type human, the wild-type rat and chi-
meric human/rat V1a receptors (CRs 1^4), were incubated with ligand, [3H]AVP, in the absence or presence of increasing concentration of
AVP and OPC-21268. At least seven concentrations of each ligand were tested, and the points were chosen to be the linear portion of displace-
ment curve. Ki values were generated using the iterative curve-¢tting program LIGAND [13]. Each value represents either the mean or the
mean þ S.E.M. of the data from at least 2^3 di¡erent experiments performed in duplicate.
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Tris^HCl, 1 mM MgCl2, pH 7.4) [12]. The mixture was then centri-
fuged at 1000Ug at 4‡C for 10 min to remove nuclei. The supernatant
was centrifuged at 35 000Ug for 20 min at 4‡C and the pellet was
resuspended in the binding bu¡er (100 mM Tris^HCl, pH 8.0, 5 mM
MgCl2, 1 mM EDTA, 0.1% (w/v) bovine serum albumin). The protein
concentration was measured using the bicinchoninic acid protein as-
say kit (Pierce, Rockford, IL, USA).
2.5. Radioligand binding assay
Radioligand binding studies were performed as described previously
[9]. Brie£y, membrane aliquots (50 Wg of protein) were incubated for
30 min at 30‡C with [3H]AVP, and either with or without a competing
drug, in a ¢nal volume of 250 Wl of the binding bu¡er. After dilution
with ice-cold bu¡er, samples were immediately ¢ltered through What-
man GF/C glass ¢ber ¢lters with a Brandel cell harvester (Model-30,
Gaithersburg, MD, USA). Each ¢lter was collected and the radio-
activity was measured. Competition experiments were carried out at
about 8.2 nM [3H]AVP which is approximately equal to the Kd of the
ligand. At this concentration, non-speci¢c binding, de¢ned as that
occurring in the presence of 10 WM AVP, represented less than 20%
of total binding. Binding assays were performed in duplicate at all
times. Data were analyzed by the iterative non-linear regression pro-
gram, LIGAND [13].
3. Results and discussion
3.1. A⁄nities of OPC-21268 for chimeric human/rat V1a
receptors
As previously reported [9], the non-peptide V1a receptor-
selective antagonist, OPC-21268, exhibited a markedly higher
a⁄nity for the wild-type rat V1a receptor (Ki = 380 nM) than
for the wild-type human V1a receptor (Ki = 140 WM). To de-
termine the domain(s) responsible for this species-dependent
di¡erence in the a⁄nity of OPC-21268 for V1a receptors, we
constructed several chimeric human/rat V1a receptors (CRs).
Structures of various human/rat V1a CRs (CR1^CR9) are
shown in Fig. 1. CR1^CR4 are human V1a receptors into
which progressively larger regions of the rat V1a receptor,
from the amino-terminal extracellular tail to TMD VII,
were introduced. The a⁄nity of OPC-21268 for the human
V1a receptor was not a¡ected by the replacement of the re-
gion spanning from the amino-terminal extracellular tail to
ECL II with that of the rat V1a receptor (CR1, CR2). In
addition, only a slight increase in the a⁄nity of OPC-21268
was observed by replacing the region spanning from the ami-
no-terminal extracellular tail to ICL III of the human V1a
receptor with that of the rat V1a receptor (CR3). However,
the replacement of the entire human V1a receptor, except for
the putative intracellular carboxy-terminus, with the rat V1a
receptor (CR4), resulted in a greatly increased a⁄nity for
OPC-21268 (a 350-fold increase in Ki compared with that
for the wild-type human V1a receptor). The a⁄nity of OPC-
21268 for CR4 (240 nM) was close to that for the wild-type
rat V1a receptor (380 nM) (Table 1).
Next, we examined the a⁄nity of OPC-21268 for CR5^
CR9. In these CRs, a part of the human V1a receptor, from
the amino-terminal extracellular tail to TMD VII, was intro-
duced into the rat V1a receptor (Fig. 1). The rat V1a-selective
binding of OPC-21268 was relatively una¡ected by the re-
placement of the region from the amino-terminal extracellular
tail to ICL III of the rat V1a receptor with that of the human
V1a receptor (CR5, CR6 and CR7). The a⁄nity of OPC-
21268 for the rat V1a receptor was slightly decreased by the
replacement of the region from the amino-terminal extracel-
lular tail to TMD VI of the rat V1a receptor with the homol-
ogous region from the human V1a receptor (CR8). However,
CR9, a CR containing the putative intracellular carboxy-ter-
minus of the rat V1a receptor with the rest of the receptor
coming from the human V1a receptor, showed a greatly de-
creased a⁄nity for OPC-21268 (a 316-fold decrease in Ki com-
pared with that for the wild-type rat V1a receptor). The af-
¢nity of OPC-21268 for CR9 (120 WM) was close to that for
the wild-type human V1a receptor (140 WM) (Table 2). Taken
together, these results suggest that the domains responsible for
the high a⁄nity binding of OPC-21268 for the rat V1a recep-
tor may reside in the region from TMD VI to VII (TMD VI^
Fig. 2. Alignment of TMD VI and VII domains of the wild-type
human and rat V1a receptors. Four amino acids, Thr-298, Val-302,
Ile-310 and Gly-337 in TMD VI^VII of the human V1a receptor
(indicated by lines), are di¡erent from those of the rat V1a receptor.
They were individually changed to the corresponding amino acids
of the rat V1a receptor, Ser-303, Leu-307, Val-315 and Ala-342, re-
spectively.
Table 2
Binding a⁄nities of AVP and OPC-21268 for the wild-type human, the wild-type rat and the chimeric human/rat V1a receptors
OPC-21268 AVP OPC/AVP
Ki (nM) Ki (nM)
Rwt 380 þ 7 1.4 þ 0.6 270
CR5 440 þ 9 3.1 þ 0.3 140
CR6 230 þ 45 0.75 þ 0.15 300
CR7 2 900 þ 360 2.1 þ 0.6 1 400
CR8 2 500 þ 400 0.81 þ 0.07 3 100
CR9 120 000 þ 11 000 1.7 þ 0.4 71 000
Hwt 140 000 1.4 þ 0.2 100 000
Cell membranes from COS-7 cells, transfected with the pME 18S expression vector containing the wild-type human, the wild-type rat and the
chimeric human/rat V1a receptors (CRs 5^9), were incubated with ligand, [3H]AVP, in the absence or presence of increasing concentration of
AVP and OPC-21268. At least seven concentrations of each ligand were tested, and the points were chosen to be the linear portion of displace-
ment curve. Ki values were generated using the iterative curve-¢tting program LIGAND [13]. Each value represents either the mean or the
mean þ S.E.M. of the data from at least 2^3 di¡erent experiments performed in duplicate.
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VII). In all CRs and wild-type V1a receptors, AVP possessed
similar binding a⁄nities (Ki = 0.26V1.6 nM).
3.2. Analysis of amino acid-substituted mutant receptors
To identify the amino acid(s) responsible for the markedly
higher a⁄nity binding of OPC-21268 for the rat V1a receptor,
four amino acids in TMD VI^VII of the wild-type human V1a
receptor, that are di¡erent from those of the wild-type rat V1a
receptor, were individually, as well as in combination,
changed to corresponding amino acids of the rat V1a recep-
tor. The positions of the mutated amino acids are indicated in
Fig. 2. The Kd values of [3H]AVP for the amino acid-substi-
tuted mutant V1a receptors were not signi¢cantly di¡erent
from that for the wild-type human V1a receptor (data not
shown). As shown in Table 3, the mutation of Ile-310 to
Val (I310V), Val-302 to Leu (V302L) and Thr-298 to Ser
(T298S) resulted in no signi¢cant di¡erences in the binding
a⁄nity of OPC-21268, compared with that for the wild-type
human V1a receptor. However, the change of Gly-337 to Ala
(G337A) increased the a⁄nity for OPC-21268 by 46-fold. In
addition, we examined double mutants (V302L/G337A,
I310V/G337A, T298S/G337A) and a triple mutant (T298S/
V302L/G337A). The a⁄nities of OPC-21268 for V302L/
G337A (6300 þ 460 nM, n = 3) and I310V/G337A (4500 þ 120
nM, n = 3) mutants were not signi¢cantly di¡erent from that
for the G337A mutant, while T298S/G337A (13 000 þ 1900
nM, n = 3) and T298S/V302L/G337A (38 000 þ 2400 nM,
n = 3) mutants showed decreased a⁄nities compared with
that for the G337A mutant. These results suggest that the
mutation of G337A is important in determining the binding
a⁄nity of OPC-21268 for the V1a receptor. In all mutants,
AVP possessed a similar binding a⁄nity (Table 3). Taken
together, the results obtained from these amino acid-substi-
tuted mutant receptors indicated that Ala-342 in TMD VII of
the rat V1a receptor is the major amino acid conferring high
a⁄nity binding of OPC-21268 to the vasopressin V1a recep-
tor. This study provides valuable information on the struc-
ture^activity relationship of the vasopressin V1a receptor and
its non-peptide, low-molecule ligand.
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no acid-substituted human V1a receptors, were incubated with ligand, [3H]AVP, in the absence or presence of increasing concentrations of
AVP and OPC-21268. At least seven concentrations of each ligand were tested, and the points were chosen to be the linear portion of displace-
ment curve. Ki values were generated using the iterative curve-¢tting program LIGAND [13]. Each value represents either the mean or the
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